Jul 1, 2024 08:35AM
Jul 1, 2024 08:35AM
Jul 1, 2024 08:35AM
Jun 3, 2024 08:35AM
Jun 3, 2024 08:35AM
Jun 3, 2024 08:35AM
Apr 3, 2024 07:02AM Kintara Therapeutics (KTRA) and TuHURA Biosciences Enter into All-Stock Merger Agreement
Apr 3, 2024 07:00AM
Apr 3, 2024 07:00AM
Feb 12, 2024 09:00AM
Oct 31, 2023 08:02AM
Oct 31, 2023 08:00AM
Jul 19, 2023 08:00AM
Feb 14, 2023 05:00PM Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update
Dec 15, 2022 08:09AM
Dec 15, 2022 08:00AM
Nov 28, 2022 08:02AM
Nov 28, 2022 08:00AM
Sep 27, 2022 08:15AM
Aug 9, 2022 09:01AM
Aug 9, 2022 09:00AM Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer
Jun 15, 2022 09:03AM
Jun 15, 2022 09:00AM
May 27, 2022 09:30AM
Nov 30, 2021 08:00AM
Nov 9, 2021 08:00AM
Sep 29, 2021 08:00AM
Sep 22, 2021 08:02AM Kintara Therapeutics (KTRA) Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Sep 22, 2021 08:00AM
Aug 17, 2021 08:00AM
Jul 1, 2021 09:30AM
Jul 1, 2021 08:19AM
Jul 1, 2021 08:00AM
Jun 3, 2021 08:08AM
Jun 3, 2021 08:00AM Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
May 26, 2021 08:02AM
May 26, 2021 08:00AM
May 4, 2021 02:43PM
May 4, 2021 02:43PM
Mar 3, 2021 02:25PM
Mar 3, 2021 02:25PM
Feb 17, 2021 08:08AM Kintara Therapeutics (KTRA) Reports Final Patient Enrollment in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
Feb 17, 2021 08:00AM
Feb 12, 2021 08:30AM
Jan 13, 2021 08:00AM
Jan 6, 2021 01:00PM
Oct 21, 2020 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All